Status:
COMPLETED
Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients
Lead Sponsor:
University of Milan
Collaborating Sponsors:
Luigi Sacco University Hospital
Conditions:
COVID19
BETA-CELL FUNCTION
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
In recent months, a new coronavirus, SARS-CoV-2, has been identified as the cause of a serious lung infection named COVID-19 by the World Health Organization. This virus has spread rapidly among the n...
Detailed Description
The project is monocentric, interventional, non-pharmacological, non-profit. Patients will be enrolled in hospital for confirmed COVID-19 infection (with reverse transcriptase-polymerase chain reactio...
Eligibility Criteria
Inclusion
- Inclusion criteria for COVID-19 positive patients
- Male and female patients with COVID19 and normal basal blood sugar, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
- Age\> 18 years and \<80 years
- Availability to informed consent and corporate privacy
- Inclusion criteria for healthy subjects
- Male and female patients not affected by COVID19, unprecedented in diabetes or impaired fasting glucose or impaired glucose tolerance
- Age\> 18 years and \<80 years
- Availability to informed consent and corporate privacy
- Exclusion criteria for COVID-19 positive patients
- Age \<18 years
- Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
- Severe liver failure
- Severe kidney failure
- Exclusion criteria for healthy subjects
- Age \<18 years
- Previous history of diabetes or impaired fasting glucose or impaired glucose tolerance
- Positivity to the nasopharyngeal swab for SARS-CoV-2
- Severe liver failure
- Severe kidney failure
- Inclusion criteria for T2D patients
- Male and female patients not affected by COVID19 with a diagnosis of type 2 diabetes
- Age\> 18 years and \<80 years
- Availability to informed consent and corporate privacy
- Exclusion criteria for T2D patients
- Age \<18 years
- Positivity to the nasopharyngeal swab for SARS-CoV-2
- Severe liver failure
- Severe kidney failure
Exclusion
Key Trial Info
Start Date :
June 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04463849
Start Date
June 30 2020
End Date
December 31 2021
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sacco University Hospital
Milan, MI, Italy, 20157